炎琥宁联合阿昔洛韦与单独采用阿昔洛韦治疗单疱病毒性角膜炎疗效比较  

Efficacies of Yanhuning combined with acyclovir and single use of acyclovir in treatment of herpes simplex virus keratitis:a comparative study

作　　者：孙昊[1] 

机构地区：[1]淮安市第二人民医院眼科,江苏淮安223001

出　　处：《中华医院感染学杂志》2012年第23期5376-5378,共3页Chinese Journal of Nosocomiology

摘　　要：目的分析比较炎琥宁联合阿昔洛韦与单独采用阿昔洛韦治疗单疱病毒性角膜炎的临床疗效。方法选取医院眼科2010年8月-2011年8月收治的单疱病毒性角膜炎50例(68眼),随机分为观察组与对照组;观察组患者25例(33眼):采用炎琥宁联合阿昔洛韦联合治疗方式治疗;对照组患者25例(35眼):采用单独阿昔洛韦治疗,每日以裂隙灯下观察患者的病情变化,根据病情连续用药10～30d,随访3个月,观察比较两组患者治疗后的临床疗效、治疗时间、不良反应、复发率。结果观察组治愈18眼,好转13眼,总有效率为93.94%,观察组治愈14眼,好转12眼,总有效率为74.29%,观察组的总有效率明显高于对照组(P<0.05),观察组的治疗时间为(16.12±3.41)d,对照组的(28.27±4.33)d,观察组的治疗时间明显低于对照组,差异有统计学意义(P<0.05);两组的不良反应发生率比较差异无统计学意义,随访3个月,观察组患者的复发率为9.09%,明显低于对照组的20.00%(P<0.05)。结论炎琥宁联合阿昔洛韦治疗单纯疱病毒性角膜炎的疗效明显优于单独采用阿昔洛韦治疗,且复发率低,值得临床推广。OBJECTIVE To observe and compare the effects of Yan hu-ning combined acyclovir and single acyclovir on treatment of herpes simplex virus keratitis （HSK）. METHODS A total of 50 patients （68 eyes） in the hospital with HSK were randomly divided into the observation group and the control group, with 25 cases in each group. The observation group （33 eyes） was treated with Yan hu-ning combined acyclovir while the control group with aeyclovir treatment. The changes of condition were observed by slit lamp, the drugs were continuously used for 10-30 days according to the condition, the follow-up for 3 months. The clinical efficacy, treatment time, adverse reactions, and the reoccurrence rate of the two groups were observed and compared after the treatment. RESULTS In the observation group, 18 eyes were cured, 13 eyes were improved, and the total effective rate was 93.94%. In the control group, 14 eyes were cured, 12 eyes were improved, and the total effective rate was 74. 29±. The response rate of observation group was obviously higher than that of the control group （P〈0.05）. The treatment time of the observation group was（16.12±3.41） d, significantly shorter than （28.27 ±4.33）d of the control group, the difference was statistically significant （P〈0.05）. The difference in the incidence of adverse reaction between the two groups was not statistically significant （P〉0.05）. After＇a three-month follow-up, the recurrence rate of the observation group was 9.09%, significantly lower than 20.00% of the eontrol group （P〉0.05）. CONCLUSION Yan hu-ning combined with acyclovir is remarkably superior to the single acyclovir in the treatment of HSK, and the reoccurrence rate is low, it is worthy of clinical promotion.

关 键 词：炎琥宁 阿昔洛韦 单疱病毒性角膜炎 疗效比较 

分 类 号：R978.1[医药卫生—药品]